Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
The Boston Cancer Summit is loaded with a stellar lineup of speakers on Apr. 16.
Same deal with the San Francisco Cancer Summit on Apr. 18.
I’m excited to announce the agendas for these special idea-and-networking forums. Hal Barron of GSK, David Schenkein of GV, Cindy Perettie of Foundation Medicine, and Ira Mellman of Genentech are a few of the outstanding speakers.
All proceeds — from tickets and sponsorships — will go directly to support cancer research at the Fred Hutchinson Cancer Research Center, a world leader. These Cancer Summits are part of the Kilimanjaro Climb to Fight Cancer. This is a philanthropic campaign mobilizing biotech executives and investors from around the country to raise $1 million for cancer research.
When you buy a ticket, you will be getting a superb learning opportunity, a rare networking opportunity, and an opportunity to support more terrific cancer biology to come at Fred Hutch.
Please take a look at the agendas below.
Thanks for your support of cancer research.
The Boston Cancer Summit, Apr. 16
Cancer R&D has never been more promising. Yet pricing and access to this new world of cancer therapy remains thorny. These issues have to be resolved if society is going to reap the benefits of this work. Come hear from some of the leading scientists, entrepreneurs, and investors about how they are thinking about the future. All ticket proceeds go to support basic science research at Fred Hutch.
REGISTER NOW: 1-6 pm, Apr. 16, Alexion Pharmaceuticals, 121 Seaport Blvd, Boston
AGENDA
1 pm Registration
1:30 pm Welcome Remarks. Alexion’s Deaidra Smith & Luke Timmerman
1:35 pm Why I’m Doing Kilimanjaro Climb to Fight Cancer (60 seconds each)
1:40 pm New Ideas for Cancer Treatment (10 minute slide presentations)
2:50 pm Cancer Investment Landscape. Separating the Hype from the Reality
3:20 pm BREAK
3:40 pm Where to Focus the Energy? A View From Pharma
4 pm How to Make It Easier for Patients to Get Access to New Therapies?
4:30 pm What’s a Fair Way to Pay for All This?
5 pm Closing Conversation on the Future for Cancer Care
5:30 pm A Word on the Kilimanjaro Climb to Fight Cancer.
5:35 pm NETWORKING
6 pm END
Buy Tickets for Boston Cancer Summit
The San Francisco Cancer Summit, Apr. 18
Cancer R&D has never been more promising. Yet pricing and access to this new world of cancer therapy remains thorny. These issues have to be resolved if society is going to reap the benefits of this work. Come hear from some of the leading scientists, entrepreneurs, and investors about how they are thinking about the future. All ticket proceeds go to support basic science research at Fred Hutch.
REGISTER NOW: 1-6 pm, Apr. 18, Biocom Bay Area, 1 Tower Place, South San Francisco
AGENDA
1 pm Registration
1:30 pm Welcome. JLABS’ Lesley Stolz & Luke Timmerman
1:35 pm Why I’m Doing Kilimanjaro Climb to Fight Cancer (60 seconds each)
1:40 pm Why Genentech is Betting Big on Personalized T-cell therapies
2:00 pm New Ideas for Cancer (10 minutes each)
3:10 pm The Future of Cancer Immunotherapy. T-cells, bispecifics, combo targeted therapies, all of the above?
3:30 pm BREAK
3:50 pm Beyond the Science: Regulatory, Commercial and Data Transformations Enabling the Cancer Revolution
4:30 pm What Will it Take for Molecular Diagnostics Reach Their Potential?
5 pm Closing Conversation on the Future for Cancer Care
5:30 pm A Word on the Kilimanjaro Climb to Fight Cancer.
5:35 pm NETWORKING
6 pm END
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
